Diametric Capital, LP Annovis Bio, Inc. Transaction History

Diametric Capital, LP

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$30.95 - $120.97 $385,575 - $1.51 Million	-12,458 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$21.55 - $96.1 $94,367 - $420,821	-4,379 Reduced 26.01%	12,458 $1.07 Million
Q1 2021 May 17, 2021	BUY	$8.15 - $38.44 $137,221 - $647,214	16,837 New	16,837 $470,000

1.2M

779K

1.77M

Ticker ANVS
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 8,163,920
Market Cap $47M
Description
Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead compound is Buntanetap, an orally administered drug, which has completed Phase 2a clinical trials for the treatment of Alzheimer's disease (AD) and Parkinson's disease, as well as is in clinical trials for Alzheimer's disease ...

Get notified when there are updates to the investment portfolio of Diametric Capital, LP, based on Form 13F filings with the SEC.

Stay updated on Diametric Capital, LP with notifications on news.